# Synnovation Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/synnovation-therapeutics

- Industry: Biotechnology
- Headquarters: Wilmington, US
- Website: https://www.synnovationtx.com/
- Total disclosed funding: $15M
- Latest round: Series A (Dec 8, 2023)
- Investors on record: 5

## About

Based in Delaware, US, and founded in 2021, Synnovation Therapeutics, Inc. operates as a biotechnology company. In December 2023, Synnovation Therapeutics, Inc. raised USD 15 million in series A funding led by new investor Third Rock Ventures, with participation from other new investors Lilly Asia Ventures, Lilly Asia Ventures, Nextech, Sirona Capital, and Cormorant Asset Management. Other unspecified investors also participated in the round.


The company develops advanced therapeutics, diagnostics, and other solutions that have a profound impact on various aspects of human health. Synnovation specializes in precision oncology developing small molecule therapies tailored to specific cancer-driving mechanisms.

Synnovation Therapeutics, Inc. will use the December 2023 funding to advance its clinical and preclinical pipeline.

## Funding rounds

- Series A, Dec 8, 2023, $15M — Third Rock Ventures, Lilly Asia Ventures, Nextech, Cormorant Asset Management, Sirona Capital

## Investors

- Third Rock Ventures (https://capitalatlas.ai/funds/third-rock-ventures) — Series A
- Lilly Asia Ventures (https://capitalatlas.ai/funds/lilly-asia-ventures) — Series A
- Nextech (https://capitalatlas.ai/funds/nextech) — Series A
- Cormorant Asset Management (https://capitalatlas.ai/funds/cormorant-asset-management) — Series A
- Sirona Capital (https://capitalatlas.ai/funds/sirona-capital) — Series A